US-based global healthcare and life sciences investor, Ampersand Capital Partners, has announced the closing of its latest fund, Ampersand 2026, with US$1.5bn in LP commitments. Ampersand’s oversubscribed 2026 fund – its twelfth primary fund since 1992 – held a single close at the hard cap less than five months after launch, and received support from a diversified and global set of institutional investors including endowments, foundations, pension plans, insurance companies, funds of funds and family offices.
Ampersand intends to continue the firm’s strategy of partnering with healthcare entrepreneurs through both majority and minority investments in companies with US$10m to US$200m in revenue and positive EBITDA.
“This strategy is focused on partnering with founders and management teams to build market-leading companies that provide mission-critical tools and services to the innovation ecosystem within healthcare and life sciences,” said Ampersand managing partner, Herb Hooper, commented,
McDermott Will & Schulte provided legal services for the fundraise.
Press release: Ampersand Closes Oversubscribed Fund at $1.5 Billion Hard Cap | Ampersand Capital Partners
